MedPath

Mind Medicine, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
$507.3M
Website

Clinical Trials

12

Active:3
Completed:5

Trial Phases

3 Phases

Phase 1:5
Phase 2:3
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (41.7%)
Phase 3
4 (33.3%)
Phase 2
3 (25.0%)

A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)

Phase 3
Recruiting
Conditions
Major Depressive Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2025-04-24
Last Posted Date
2025-08-21
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
140
Registration Number
NCT06941844
Locations
🇺🇸

Adams Clinical Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Preferred Research Partner, Fayetteville, Arkansas, United States

🇺🇸

Preferred Research Partners, Inc, Little Rock, Arkansas, United States

and more 24 locations

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Phase 3
Recruiting
Conditions
Generalized Anxiety Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2025-02-05
Last Posted Date
2025-08-28
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
250
Registration Number
NCT06809595
Locations
🇨🇿

Psyon s.r.o., Prague, Czechia

🇩🇪

Department of Psychiatry and Psychotherapy Campus Charité Mitte Charité Universitätsmedizin Berlin, Berlin, Germany

🇺🇸

Preferred Research Partners, Inc., Little Rock, Arkansas, United States

and more 15 locations

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

Phase 3
Recruiting
Conditions
Generalized Anxiety Disorder
Interventions
Other: Placebo
Drug: MM120 (LSD D-Tartrate)
First Posted Date
2024-12-18
Last Posted Date
2025-08-17
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
200
Registration Number
NCT06741228
Locations
🇺🇸

Lighthouse Psychiatry, Gilbert, Arizona, United States

🇺🇸

Kadima Neuropsychiatry Institute, La Jolla, California, United States

🇺🇸

UCSF Department of Neurology, San Francisco, California, United States

and more 29 locations

A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

Phase 2
Completed
Conditions
Anxiety Generalized
Interventions
Other: Placebo
Drug: MM-120 (LSD D-Tartrate)
First Posted Date
2022-06-07
Last Posted Date
2025-03-20
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
198
Registration Number
NCT05407064
Locations
🇺🇸

Preferred Research Partners, Little Rock, Arkansas, United States

🇺🇸

Irvine Center for Clinical Research, Irvine, California, United States

🇺🇸

Kadima Neuropsychiatry Institute, La Jolla, California, United States

and more 17 locations

Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

Phase 2
Completed
Conditions
Attention Deficit Disorder
ADHD
Interventions
Other: Placebo
First Posted Date
2022-01-21
Last Posted Date
2025-04-13
Lead Sponsor
Mind Medicine, Inc.
Target Recruit Count
53
Registration Number
NCT05200936
Locations
🇳🇱

Maastricht University, Maastricht, Netherlands

🇨🇭

University Hospital Basel, Basel, Switzerland

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.